[Form 4] Mesa Laboratories Inc Insider Trading Activity
Shannon Hall, a director of Mesa Laboratories, reported stock-based compensation transactions dated 08/15/2025. The filing shows 1,404 restricted stock units (RSUs) vested on that date and were converted into 1,404 shares of common stock with a reported acquisition price of $0. After the transaction Hall beneficially owns 4,189 shares directly. The filing also reports an additional grant of 2,784 RSUs that vest on 08/15/2026 and are recorded as 2,784 shares of underlying common stock. The Form 4 was executed under power of attorney and signed on 08/18/2025.
Shannon Hall, direttore di Mesa Laboratories, ha comunicato operazioni di compenso basato su azioni datate 15/08/2025. La comunicazione indica che 1.404 unità azionarie vincolate (RSU) sono maturate in tale data e sono state convertite in 1.404 azioni ordinarie con prezzo di acquisizione riportato pari a $0. Dopo l'operazione, Hall detiene 4.189 azioni in proprietà diretta. Il documento segnala inoltre una concessione aggiuntiva di 2.784 RSU che matureranno il 15/08/2026 e sono registrate come 2.784 azioni ordinarie sottostanti. Il Modulo 4 è stato firmato per procura in data 18/08/2025.
Shannon Hall, directora de Mesa Laboratories, informó transacciones de compensación en acciones con fecha 15/08/2025. El reporte muestra que 1.404 unidades restringidas de acciones (RSU) vencieron en esa fecha y se convirtieron en 1.404 acciones ordinarias con un precio de adquisición informado de $0. Tras la transacción, Hall posee 4.189 acciones en propiedad directa. El formulario también informa una concesión adicional de 2.784 RSU que vencerán el 15/08/2026 y se registran como 2.784 acciones ordinarias subyacentes. El Formulario 4 fue firmado por poder el 18/08/2025.
Mesa Laboratories의 이사 Shannon Hall이 2025년 8월 15일자 주식 기반 보상 거래를 보고했습니다. 보고서에 따르면 해당 일자에 1,404개의 제한부주식단위(RSU)가 성과조건을 충족하여 1,404주의 보통주로 전환되었고 취득가는 $0로 기재되어 있습니다. 거래 후 Hall은 직접 4,189주를 보유하고 있습니다. 또한 추가로 2,784 RSU가 부여되어 2026년 8월 15일에 성과가 확정되며 기초 보통주 2,784주로 기록되어 있다고 보고되었습니다. Form 4는 위임장에 따라 작성되어 2025년 8월 18일에 서명되었습니다.
Shannon Hall, administratrice de Mesa Laboratories, a déclaré des opérations de rémunération en actions datées du 15/08/2025. Le dépôt indique que 1 404 unités d'actions restreintes (RSU) ont acquis à cette date et ont été converties en 1 404 actions ordinaires avec un prix d'acquisition déclaré de 0 $. Après la transaction, Hall détient directement 4 189 actions. Le document signale également une attribution supplémentaire de 2 784 RSU qui acquerront le 15/08/2026 et sont enregistrées comme 2 784 actions ordinaires sous-jacentes. Le formulaire 4 a été signé par procuration le 18/08/2025.
Shannon Hall, Direktorin von Mesa Laboratories, meldete aktienbasierte Vergütungs-Transaktionen mit Datum 15.08.2025. Die Einreichung zeigt, dass 1.404 Restricted Stock Units (RSUs) an diesem Datum fällig wurden und in 1.404 Stammaktien umgewandelt wurden, mit einem angegebenen Erwerbspreis von $0. Nach der Transaktion besitzt Hall direkt 4.189 Aktien. Die Meldung berichtet außerdem über eine zusätzliche Zuteilung von 2.784 RSUs, die am 15.08.2026 fällig werden und als 2.784 zugrunde liegende Stammaktien erfasst sind. Das Formular 4 wurde per Vollmacht ausgeführt und am 18.08.2025 unterschrieben.
- Timely disclosure of insider transaction with filing executed shortly after the transaction date
- Vested RSUs converted to shares, increasing the reporting person's direct ownership to 4,189 shares
- No cash paid for the vested RSUs as reported (price = $0)
- Future RSUs disclosed with clear vesting date of 08/15/2026
- None.
Insights
TL;DR: Routine RSU vesting increased a director's direct share count by 1,404 shares; no cash paid.
The transaction reflects standard equity compensation mechanics rather than a market-moving event. The vested RSUs converted to 1,404 shares at a reported price of $0, increasing Shannon Hall's direct holdings to 4,189 shares. An additional 2,784 RSUs remain scheduled to vest on 08/15/2026, representing future dilution when settled. For investors, this is a disclosure of insider alignment via equity compensation, but the absolute size is small relative to public-company float and does not indicate a change in company operations or financial condition.
TL;DR: This is a standard director equity vesting disclosure; timing and POA signature are properly documented.
The Form 4 documents customary rollout of restricted stock units to a director with clear vesting dates and an executed filing under power of attorney. The filing shows no sale or cash purchase; vested units converted into shares and additional RSUs remain outstanding with a one-year vesting horizon. From a governance perspective the filing demonstrates routine director compensation and timely reporting, with no red flags such as accelerated dispositions or unexpected changes in control.
Shannon Hall, direttore di Mesa Laboratories, ha comunicato operazioni di compenso basato su azioni datate 15/08/2025. La comunicazione indica che 1.404 unità azionarie vincolate (RSU) sono maturate in tale data e sono state convertite in 1.404 azioni ordinarie con prezzo di acquisizione riportato pari a $0. Dopo l'operazione, Hall detiene 4.189 azioni in proprietà diretta. Il documento segnala inoltre una concessione aggiuntiva di 2.784 RSU che matureranno il 15/08/2026 e sono registrate come 2.784 azioni ordinarie sottostanti. Il Modulo 4 è stato firmato per procura in data 18/08/2025.
Shannon Hall, directora de Mesa Laboratories, informó transacciones de compensación en acciones con fecha 15/08/2025. El reporte muestra que 1.404 unidades restringidas de acciones (RSU) vencieron en esa fecha y se convirtieron en 1.404 acciones ordinarias con un precio de adquisición informado de $0. Tras la transacción, Hall posee 4.189 acciones en propiedad directa. El formulario también informa una concesión adicional de 2.784 RSU que vencerán el 15/08/2026 y se registran como 2.784 acciones ordinarias subyacentes. El Formulario 4 fue firmado por poder el 18/08/2025.
Mesa Laboratories의 이사 Shannon Hall이 2025년 8월 15일자 주식 기반 보상 거래를 보고했습니다. 보고서에 따르면 해당 일자에 1,404개의 제한부주식단위(RSU)가 성과조건을 충족하여 1,404주의 보통주로 전환되었고 취득가는 $0로 기재되어 있습니다. 거래 후 Hall은 직접 4,189주를 보유하고 있습니다. 또한 추가로 2,784 RSU가 부여되어 2026년 8월 15일에 성과가 확정되며 기초 보통주 2,784주로 기록되어 있다고 보고되었습니다. Form 4는 위임장에 따라 작성되어 2025년 8월 18일에 서명되었습니다.
Shannon Hall, administratrice de Mesa Laboratories, a déclaré des opérations de rémunération en actions datées du 15/08/2025. Le dépôt indique que 1 404 unités d'actions restreintes (RSU) ont acquis à cette date et ont été converties en 1 404 actions ordinaires avec un prix d'acquisition déclaré de 0 $. Après la transaction, Hall détient directement 4 189 actions. Le document signale également une attribution supplémentaire de 2 784 RSU qui acquerront le 15/08/2026 et sont enregistrées comme 2 784 actions ordinaires sous-jacentes. Le formulaire 4 a été signé par procuration le 18/08/2025.
Shannon Hall, Direktorin von Mesa Laboratories, meldete aktienbasierte Vergütungs-Transaktionen mit Datum 15.08.2025. Die Einreichung zeigt, dass 1.404 Restricted Stock Units (RSUs) an diesem Datum fällig wurden und in 1.404 Stammaktien umgewandelt wurden, mit einem angegebenen Erwerbspreis von $0. Nach der Transaktion besitzt Hall direkt 4.189 Aktien. Die Meldung berichtet außerdem über eine zusätzliche Zuteilung von 2.784 RSUs, die am 15.08.2026 fällig werden und als 2.784 zugrunde liegende Stammaktien erfasst sind. Das Formular 4 wurde per Vollmacht ausgeführt und am 18.08.2025 unterschrieben.
FAQ
What did Shannon Hall report on Form 4 for MLAB?
Did Shannon Hall purchase shares on 08/15/2025 for MLAB?
Are there additional RSUs disclosed for Shannon Hall?
What is the reporting person’s relationship to Mesa Laboratories (MLAB)?
When was the Form 4 signed and who signed it?
